HCV Screening and Treatment Uptake among Patients in HIV care During 2014-2015.

BACKGROUND: Despite the high prevalence of Hepatitis C Virus (HCV) among persons living with HIV (PWH), the prevalence of HCV screening, treatment, and sustained virologic response (SVR) is unknown. This study aims to characterize the continuum of HCV screening and treatment among PWH in HIV care.

SETTING: Adult patients enrolled at 12 sites of the HIV Research Network located in three regions of the United States were included.

METHODS: We examined the prevalence of HCV screening, HCV coinfection, direct-acting antiretroviral (DAA) treatment, and SVR-12 between 2014-15. Multivariate logistic regression was performed to identify characteristics associated with outcomes, adjusted for site.

RESULTS: Among 29,071 PWH (age 18-87, 74.8% male, 44.4% black), 77.9% were screened for HCV antibodies; 95% of those screened had a confirmatory HCV-RNA viral load test. Among those tested, 61% were determined to have chronic HCV. We estimate that only 23.4% of those eligible for DAA were prescribed DAA, but only 17.8% of those eligible evidenced initiating DAA treatment. Those who initiated treatment achieved SVR-12 at a rate of 95.2%. Blacks and people who inject drugs (PWID) were more likely to be screened for HCV than whites or those with heterosexual risk. Persons over age 40, whites, Hispanics, and PWID (AOR 8.70 [7.74-9.78]) were more likely to be coinfected than their counterparts. When examining treatment with DAA, persons over age 50, on ART (AOR, 2.27 [1.11-4.64]), with HIV-1 RNA <400 (AOR, 2.67 [1.71-4.18]), and those with higher Fib-4 scores were more likely to be treated with DAA.

CONCLUSIONS: While rates of screening for HCV among PWH are high, screening remains far from comprehensive. Rates of SVR were high, consistent with previously published literature. Additional programs to improve screening and make treatment more widely available will help reduce the impact of HCV morbidity among PWH.